NRx Pharmaceuticals Inc. (NRXP)
NASDAQ: NRXP
· Real-Time Price · USD
2.88
0.21 (7.87%)
At close: Aug 15, 2025, 3:59 PM
2.87
-0.34%
After-hours: Aug 15, 2025, 07:40 PM EDT
NRx Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | 4K | n/a | n/a | n/a | 8K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 2K | n/a | 1K | 1K | 1K | 2K | 1K | 1K | 1K | 1K | 1K | 1K | 395.00 | 638.00 | 967.00 | n/a |
Gross Profit | n/a | 2K | n/a | -1K | -1K | -1K | -2K | -1K | -1K | -1K | -1K | -1K | -1K | -395 | -638 | -967 | n/a |
Operating Income | -3.85M | -2.43M | -3.02M | -7.05M | -6M | -4.41M | -5.81M | -8.19M | -9.44M | -9.89M | -9.14M | -9.6M | -15.71M | -52.98M | -20.1M | -17.12M | -25.61M |
Interest Income | 4K | 4K | 6K | 7K | 27K | 74K | 119K | 145K | 156K | 130K | 95K | 23K | n/a | n/a | 368.00 | 107.00 | n/a |
Pretax Income | -5.51M | -9.08M | -1.62M | -7.9M | -6.53M | -4.34M | -6.06M | -8.72M | -11.04M | -10.24M | -9.08M | -6.98M | -13.45M | -30.79M | -37.05M | -118K | -25.49M |
Net Income | -5.51M | -9.08M | -1.62M | -7.9M | -6.53M | -4.33M | -6.06M | -8.72M | -11.04M | -10.24M | -9.08M | -6.98M | -13.45M | -30.79M | -37.05M | -118K | -25.49M |
Selling & General & Admin | 2.94M | 2.6M | 2.41M | 4.25M | 4.25M | 1.87M | 2.49M | 4.07M | 5.79M | 5.43M | 5.01M | 6.64M | 10.22M | 46.56M | 13.82M | 12.46M | 2.1M |
Research & Development | 804K | 1.04M | 611K | 2.8M | 1.75M | 2.53M | 3.31M | 3.87M | 3.65M | 4.46M | 4.13M | 2.96M | 5.48M | 6.41M | 6.28M | 4.66M | 2.91M |
Other Expenses | 100K | -1.2M | n/a | n/a | n/a | n/a | n/a | 250K | n/a | n/a | n/a | n/a | n/a | 603.00 | n/a | n/a | 235.58K |
Operating Expenses | 3.85M | 2.43M | 3.02M | 7.05M | 6M | 4.41M | 5.81M | 8.19M | 9.44M | 9.89M | 9.14M | 9.6M | 15.71M | 52.98M | 20.1M | 17.12M | 4.24M |
Interest Expense | n/a | n/a | n/a | n/a | 230K | 80K | 40K | n/a | n/a | n/a | n/a | n/a | 3K | 2.34K | 5.37K | 5.11K | 5K |
Selling & Marketing Expenses | n/a | 1K | n/a | n/a | -1K | -1K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 3.85M | 2.43M | 3.02M | 7.05M | 6M | 4.41M | 5.81M | 8.19M | 9.44M | 9.89M | 9.14M | 9.6M | 15.71M | 52.98M | 20.1M | 17.12M | 25.48M |
Income Tax Expense | n/a | n/a | n/a | n/a | -42.28K | -1.39M | 40K | n/a | n/a | n/a | -58K | n/a | n/a | n/a | 5.37K | n/a | -21.36M |
Shares Outstanding (Basic) | 16.41M | 10.52M | 10.97M | 10.52M | 8.85M | 83.92M | 8.2M | 73.22M | 67.45M | 66.45M | 64.88M | 65.73M | 63.67M | 51.74M | 54.81M | 41.73M | 3.57M |
Shares Outstanding (Diluted) | 16.41M | 10.52M | 10.97M | 10.52M | 8.85M | 83.92M | 8.2M | 73.22M | 67.45M | 66.45M | 66.45M | 65.73M | 63.67M | 51.74M | 54.81M | 42.49M | 35.66M |
EPS (Basic) | -0.34 | -0.86 | -0.15 | -0.75 | -0.74 | -0.05 | -0.74 | -0.12 | -0.19 | -0.09 | -0.14 | -0.07 | -0.18 | -0.6 | -0.38 | -61.3 | -0.71 |
EPS (Diluted) | -0.34 | -0.86 | -0.15 | -0.75 | -0.74 | -0.05 | -0.74 | -0.12 | -0.19 | -0.09 | -0.14 | -0.07 | -2.1 | -0.6 | -0.38 | -64.3 | -7.1 |
EBITDA | -5.51M | -9.08M | -1.62M | -7.9M | -6.3M | -4.25M | -6.02M | -8.72M | -11.04M | -10.24M | -9.08M | -6.98M | -13.44M | -30.79M | -37.04M | -112K | -25.48M |
EBIT | -5.51M | -9.08M | -1.62M | -7.9M | -6.3M | -4.25M | -6.02M | -8.72M | -11.04M | -10.24M | -9.08M | -6.98M | -13.45M | -30.79M | -37.04M | -113K | -25.48M |
Depreciation & Amortization | n/a | 1K | 2K | 1K | 1K | 1K | 2K | 1K | 1K | 1K | 1K | 1K | 1K | 395.00 | 638.00 | 967.00 | n/a |